IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Purchases 26,581 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 26,581 shares of IRIDEX stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average price of $1.16 per share, with a total value of $30,833.96. Following the completion of the transaction, the insider owned 177,497 shares of the company’s stock, valued at $205,896.52. This represents a 17.61% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Price Performance

Shares of NASDAQ IRIX opened at $0.90 on Friday. The stock has a market capitalization of $15.78 million, a price-to-earnings ratio of -4.49 and a beta of 0.67. The firm’s 50 day simple moving average is $0.73 and its 200-day simple moving average is $0.95. IRIDEX Corporation has a 12 month low of $0.61 and a 12 month high of $1.65.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million. Analysts anticipate that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Institutional Trading of IRIDEX

Large investors have recently made changes to their positions in the company. United Capital Financial Advisors LLC purchased a new position in IRIDEX in the 2nd quarter valued at $41,000. Weber Capital Management LLC ADV acquired a new stake in shares of IRIDEX in the second quarter valued at about $206,616. Diversify Advisory Services LLC purchased a new position in shares of IRIDEX in the second quarter worth about $30,000. Bank of New York Mellon Corp purchased a new position in shares of IRIDEX in the second quarter worth about $29,000. Finally, Renaissance Technologies LLC boosted its position in IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares during the last quarter. 20.10% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.00.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.